Clinical examination of the therapeutic efficacy, tolerability and safety of Varumin® 1 and 2 oral solutions (Inter-Evrogeneks) in combination with therapy with polyvitamin – antioxidant therapy in biological (PCR) proved a HPV high-risk type infection, with or without CIN I confirmed by biopsy
Department of gynecology and maternity, Vodnjanska bb
University of St. Cyril and Methodius, Skopje, Macedonia
Varumin® is a new hope for all patients with MULTIPLE SCLEROSIS.
Small, but important study, completed recently, found out that the immunomodulatory effect of Varuminu® ® has a beneficial effect in the case of this particular disease.
Inter-Evrogeneks presents the first product, which managed to completely eliminate the presence of all symptoms typical of MS.
Study name: Clinical examination of the therapeutic efficacy, tolerability and safety of Varumin® in patients with PCR showed an infection of HPV type at high risk, with or without a biopsy CIN. So far, all the results confirm the expectations.
This first statistical part is the beginning of that the Varumin® is so functional, and the results of his work testify the veracity of the study.
Expert opinion: What does the expert Prof. Dr. SCI Sibin Ilic say about Varumin®?